For people who have severe congenital protein C deficiency, protein C replacement therapies are available, which is indicated and approved for use in the United States and Europe for the prevention of<unk> . Protein C replacement is often in combination with anticoagulation therapy of injectable low molecular weight heparin or oral warfarin. Before initiating warfarin therapy, a few days of therapeutic heparin may be administered to prevent warfarin necrosis and other progressive or recurrent thrombotic complications. Complications of prevention The amount of fresh frozen plasma required to reverse disseminated intravascular coagulation associated with<unk>  may lead to complications of fluid overload and death, especially in neonates, such as transfusion-related acute lung injury. Exposure to multiple plasma donors over time increases the cumulative risk for transfusion-associated viral infection and allergic reaction to donor proteins found in fresh frozen plasma. Allergic reactions and alloantibody formation are also potential complications, as with any protein replacement therapy. Concomitant warfarin therapy in subjects with congenital protein C deficiency is associated with an increased risk of warfarin skin necrosis.
Purpura fulminans
Acne fulminans
Pyoderma gangrenosum
Leukemia cutis
Visceral larva migrans
Dandruff
Erythema multiforme minor
Ecthyma gangrenosum